Transfer of in vitro expanded T lymphocytes after activation with dendritomas prolonged survival of mice challenged with EL4 tumor cells

International Journal of Oncology

Volumn 31, Issue 1, 2007, Pages 193-197

  Li, Jinhua ^a   Theofanous, Leigh ^a   Stickel, Sara ^a   Bouton Verville, Hilary ^a   Burgin, Kelly E ^a   Jakubchak, Susan ^a   Wagner, Thomas E ^a,b   Wei, Yanzhang ^a,b  

^a GREENVILLE HOSPITAL SYSTEM   (United States)

^b CLEMSON UNIVERSITY   (United States)

Author keywords

Adoptive transfer; Dendritoma; In vitro expansion; Leukemia; T cell

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL; ARTICLE; CELL FUSION; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DENDRITIC CELL; DRUG SCREENING; FEMALE; IMMUNOLOGY; LYMPH NODE; LYMPHOCYTE ACTIVATION; METHODOLOGY; MOUSE; MOUSE STRAIN; NEOPLASM; PHENOTYPE; T LYMPHOCYTE; TRANSPLANTATION; TUMOR CELL LINE;

ANIMALS; ANTIGENS, CD28; ANTIGENS, CD3; CELL FUSION; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; FEMALE; IMMUNOTHERAPY, ADOPTIVE; LYMPH NODES; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED STRAINS; NEOPLASMS; PHENOTYPE; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34548552616     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.31.1.193     Document Type: Article

References (27)

1. Steinman R: The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 9: 271-296, 1997.
2. Macatonia S, Taylor P, Knight S, et al: Primary stimulation by dendritic cells induces antiviral proliferative and cytotoxic T cell responses in vitro. J Exp Med 169: 1255-1264, 1989.
3. Mehta-Damani A, Markowicz S and Engleman E: Generation of antigen-specific CD8+ CTLs from naïve precursors. J Immunol 153: 996-1003, 1994.
4. Porgador A and Gilboa E: Bone marrow-generated dendritic cells pulsed with a class I-restricted peptide are potent inducers of cytotoxic T lymphocytes. J Exp Med 182: 255-260, 1995.
5. Granucci F, Foti M and Ricciardi-Castagnoli P: Dendritic cell biology. Adv Immunol 88: 193-233, 2005.
6. Duez C, Gosset P and Tonnel AB: Dendritic cells and toll-like receptors in allergy and asthma. Eur J Dermatol 16: 12-16, 2006.
7. Sznol M: Emerging concepts in cancer vaccine development. Principles Practice Oncol 13: 1-14, 1999.
8. Holmes LM, Li J, Sticca RP, et al: A rapid, novel strategy to induce tumor cell specific cytotoxic T lymphocyte (CTL) responses using instant dendritomas. J Immunother 24: 122-129, 2001.
9. Li J, Holmes LM, Franek KJ, et al: Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol Immunother 50: 456-462, 2001.
10. Wei Y, Sticca RP, Holmes LM, et al: Dendritoma vaccination combined with low dose interleukin-2 in metastatic melanoma patients induced immunological and clinical responses. Int J Oncol 28: 585-593, 2006.
11. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al: Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 6: 383-393, 2006.
12. Macary PA, Too CT and Dai X: Targeting tumours by adoptive transfer of immune cells. Clin Exp Pharmacol Physiol 33: 569-574, 2006.
13. Tey SK, Bollard CM and Heslop HE: Adoptive T-cell transfer in cancer immunotherapy. Immunol Cell Biol 84: 281-289, 2006.
14. Chou T, Chang AE and Shu S: Generation of therapeutic T lymphocytes from tumor-bearing mice by in vitro sensitization: culture requirements and characterization of immunologic specificity. J Immunol 140: 2453-2461, 1998.
15. Yoshizawa H, Chang AE and Shu S: Cellular interactions in effector cell generation and tumor regression mediated by anti-CD3/interleukin 2 activated tumor draining lymph node cells. Cancer Res 52: 1129-1136, 1992.
16. + cells generated from tumor-primed lymph nodes using antiCD3/CD28 monoclonal antibodies. J Immunother 25: 304-313, 2002.
17. Rosenberg SA, Spiess P and Lafreniere P: A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321, 1986.
18. Topalian SL, Solomon D and Rosenberg SA: Tumor-specific cytolysis by lymphocytes infiltrating human melanomas. J Immunol 142: 3714-3725, 1989.
19. Chang AE, Aruga A, Cameron MJ, et al: Adoptive immunotherapy with vaccine-primed lymph node cells secondarily activated with anti-CD3 and interleukin-2. J Clin Oncol 15: 798-807, 1997.
20. Dudley ME, Wunderlich JR, Robbins PF, et al: Cancer regression and autoimmunity in patients ater clonal repopulation with antitumor lymphocytes. Science 298: 850-854, 2002.
21. Robbins PF, Dudley ME, Wunderlich J, et al: Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfusion therapy. J Immunol 173: 7125-7130, 2004.
22. Ito F, Carr A, Svensson H, Yu J, et al: Antitumor reactivity of anti-CD3/anti-CD28 bead-activated lymphoid cells: implications for cell therapy in a murine model. J Immunother 26: 222-233, 2003.
23. Foster AE and Rooney CM: Improving T cell therapy for cancer. Expert Opin Biol Ther 6: 215-229, 2006.
24. + T cells. J Clin Invest 115: 1616-1626, 2005.
25. + CTL reactive against tumor cells expressing a naturally occurring rejection epitope. J Immunol 167: 4286-4292, 2001.
26. Beck KE, Blansfield JA, Tran KQ, et al: Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen-4. J Clin Oncol 24: 2283-2289, 2006.
27. Graca L and Waldmann H: Reprogramming the immune system using antibodies. Methods Mol Biol 333: 247-268, 2006.